Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. RESEARCH DESIGN AND METHODS: In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. RESULTS: The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was −1.08 ± 0.06% (−11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −0.76 ± 0.06% (−8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and −0.63 ± 0.06% (−6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% (53 mmol/mol) versus glargine (P < 0.001). Body weight decreased with dulaglutide and increased with glargine. Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal. Increases in pancreatic enzymes were observed for dulaglutide. Incidence of nausea (15.4, 7.7, and 1.5%) and diarrhea (10.6, 9.2, and 5.7%) were more common with dulaglutide 1.5 mg and 0.75 mg than with glargine. CONCLUSIONS: Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“In trials analyzing the addition of an injectable GLP-1 RA, dual GIP and GLP-1 RA, or insulin in people needing further glucose lowering, glycemic efficacies of GLP-1 RAs and the dual GIP and GLP-1 RA were similar to or greater than that of basal insulin (123-130).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“It is worth mentioning that in the AWARD-2 study, there were several cases of pancreatitis caused by DUL (112).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [112]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699 · cited 11×
“%) at least once after baseline; dulaglutide-neutralizing antibodies developed in 5, but no native sequence GLP-1neutralizing–antibodies developed.”
BackgroundInfluentialRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Thomas, G. E., Westfall, P. H., & Young, S. S. (1994) · The Statistician · doi:10.2307/2348369 · Cited by 513
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Metadata
- Authors
- Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V.
- Affiliations
- University of Bari Aldo Moro (IT)
- Evangelismos-Polyclinic, Athens General Hospital, Athens, Greece
- Chang Gung Memorial Hospital (TW)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Neuilly-Sur-Seine Cedex, France
- Corresponding author
- Pechtner, Valeria
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-06-18
- Volume
- 38
- Issue
- 12
- Pages
- 2241-2249
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W906438903
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 17 · 2023: 20 · 2022: 19 · 2021: 21 · 2020: 22 · 2019: 28 · 2018: 29 · 2017: 27 · 2016: 23 · 2015: 17
- FWCI
- 27.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, insulin glargine, type 2 diabetes, GLP-1 receptor agonists, metformin, glimepiride, HbA1c, glycemic control, non-inferiority, hypoglycemia, body weight, pancreatic enzymes, nausea, drug safety, dose comparison
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Recombinant Fusion Proteins, Sulfonylurea Compounds, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). https://app.cochat.ai/papers/10.2337/dc14-1625
- The paper
- Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015). Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. https://doi.org/10.2337/dc14-1625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.